Published in Clin Vaccine Immunol on May 30, 2007
Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin (2011) 1.11
The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz (2002) 4.51
Control of Chagas disease. World Health Organ Tech Rep Ser (2002) 4.00
Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg (1987) 2.66
Where do we stand on the autoimmunity hypothesis of Chagas disease? Trends Parasitol (2005) 1.78
Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol (1998) 1.53
Molecular karyotype of clone CL Brener chosen for the Trypanosoma cruzi genome project. Mol Biochem Parasitol (1995) 1.48
Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun (2002) 1.45
Antigenic polymorphism of Trypanosoma cruzi: clonal analysis of trypomastigote surface antigens. Eur J Immunol (1984) 1.34
DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun (2001) 1.24
DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect Immun (2000) 1.23
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun (2002) 1.18
Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther (2004) 1.14
Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun (2005) 1.13
Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect Immun (2004) 1.11
During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect Immun (2002) 1.09
The surface glycoproteins of Trypanosoma cruzi encode a superfamily of variant T cell epitopes. J Immunol (1997) 1.07
Detection of live Trypanosoma cruzi in tissues of infected mice by using histochemical stain for beta-galactosidase. Infect Immun (1999) 1.07
A method for counting and concentrating living Trypanosoma cruzi in blood lysed with ammonium chloride. J Parasitol (1974) 1.04
Trypanosoma cruzi: paninfectivity of CL strain during murine acute infection. Exp Parasitol (1996) 1.03
Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes. Vaccine (2003) 0.99
Immunization with recombinant paraflagellar rod protein induces protective immunity against Trypanosoma cruzi infection. Vaccine (2003) 0.96
Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice. Immunol Lett (2005) 0.92
The surface protein superfamily of Trypanosoma cruzi stimulates a polarized Th1 response that becomes anergic. J Immunol (1999) 0.91
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120. J Virol (2012) 1.21
Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 1.17
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine (2009) 1.12
During Trypanosoma cruzi infection CD1d-restricted NK T cells limit parasitemia and augment the antibody response to a glycophosphoinositol-modified surface protein. Infect Immun (2002) 1.09
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01
Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. J Virol (2013) 0.91
Both CD1d antigen presentation and interleukin-12 are required to activate natural killer T cells during Trypanosoma cruzi infection. Infect Immun (2005) 0.90
Treatment with alpha-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive. J Immunol (2002) 0.89
Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine (2008) 0.84
NK cell activation and protection occur independently of natural killer T cells during Trypanosoma cruzi infection. Int Immunol (2005) 0.84
During acute Trypanosoma cruzi infection highly susceptible mice deficient in natural killer cells are protected by a single alpha-galactosylceramide treatment. Immunology (2006) 0.81
Isolation of monoclonal antibodies with predetermined conformational epitope specificity. PLoS One (2012) 0.81
Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther (2012) 0.77
How dental team members describe adverse events. J Am Dent Assoc (2016) 0.75
Classifying Adverse Events in the Dental Office. J Patient Saf (2017) 0.75
Trypanosoma cruzi-infected individuals demonstrate varied antibody responses to a panel of trans-sialidase proteins encoded by SA85-1 genes. Acta Trop (2005) 0.75